Furthermore, receptor tyrosine kinases (RTKs) found in ROS1-positive cancers are druggable targets and TKIs (such as crizotinib) therefore emerged as promising agents for the treatment of these cancers [8]. The gene discussed is ROS1; the disease is cancer.